Background: Women with polycystic ovary syndrome (PCOS) are almost three times more likely to be obese than those without PCOS. However, we have no specific interventions to induce weight loss so far, and rely on drugs used to treat other symptoms of the syndrome or obesity in the general population.
Introduction
The World Health Organization (WHO) has declared 'obesity is one of the greatest public health challenges of the 21st century' 1 . Obesity is particularly a problem for women with PCOS as they have a 2.8-fold increased prevalence (50%-80%) compared to women who do not have the syndrome 2, 3 . In the original description of the syndrome by Stein and Leventhal in 1935, 60% (three of the five women for whom habitus was reported) were obese 4 . Unfortunately, this obesity, which is so common in women with PCOS, exacerbates symptoms of the syndrome 5 . Hyperinsulinaemia reduces circulating levels of sex hormone-binding globulin, increasing free testosterone, which inhibits follicular maturation with consequent menstrual irregularity and infertility. Insulin also augments the thecal androgen production responsible for acne and hirsutism 6 . In the longer term, hyperinsulinaemia increases the risks of diabetes (type II and gestational), coronary heart disease and endometrial cancer [7] [8] [9] [10] [11] . Weight loss is therefore fundamental to the management of women with PCOS 2, 12 .
Aside from increasing the severity of the symptoms of PCOS, obesity reduces the effectiveness of fertility treatment (ovulation induction and in vitro fertilization) and increases the risk of pregnancy complications 10, 13 . For these reasons, fertility treatment is withheld by the National Health Service (NHS) for those with a body mass index (BMI) > 30 kg/m 2 . Although lifestyle management is the first line therapy in PCOS for prevention of weight gain and for weight loss 14 , the efficacy of lifestyle management for established obesity has been limited in PCOS in the general population 15 ,and new approaches are needed 16 .Moreover, for some women with PCOS and obesity, lifestyle modifications are not effective, or for the women who cannot or are not willing to modify their lifestyle, the pharmacologic therapy to induce weight loss is also very important.
Bariatric surgery can also effectively attenuates PCOS and its clinical symptomatology including hirsutism and menstrual irregularity in severely women with obesity 17 .The goal for weight reduction in women with PCOS is to improve insulin resistance, reduce hyperandrogenism and alleviate PCOS clinical severity 15, 18, 19 .However, because we do not understand the mechanisms responsible for obesity in women with this condition, we are forced to rely on drugs used to treat other symptoms of the syndrome or those licensed to treat obesity in the general population 7 . Based on familiarity and cost, metformin is widely used for this purpose in women with PCOS 20 . Other drugs used include orlistat, inositol and liraglutide [21] [22] [23] ; however, their comparative efficacy in women with PCOS is unknown. We have conducted the first systematic review and meta-analysis to compare the effects of these drugs on weight loss in women with PCOS and overweight/obesity.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to conduct our systematic review 24 .
Study eligibility criteria
We included studies that 1) used a randomised, parallel group trial design; 2) were conducted in the following settings: clinic, hospital, medical centre or community; 3) recruited adults/adolescents who have obesity/overweight with PCOS; and 4) included placebo or metformin as the control arm. Where studies reported similar or overlapping data, only the latest or those with a larger sample size were considered for this review.
The outcomes of interest included BMI, weight, waist circumference and waist-to-hip ratio (WHR).
Literature search methodology
We searched the following databases for published articles and conference abstracts and proceedings in consultation with a search methodologist: MEDLINE (Ovid), 
Study selection
After a primary screening of titles and abstracts (by F.W., Y.W., Y.Z and F.Q.), the full texts of all potentially eligible studies were retrieved. Three review authors (F.W., Y.W., and Y.Z.) independently examined and selected the eligible articles in compliance with the inclusion criteria for the current review. Study investigators were contacted if clarification regarding details of the study was needed. Disagreement with respect to study eligibility was resolved via discussion with the other reviewer (F.Q.). The selection process is presented in a PRISMA diagram.
Data extraction
Two review authors (F.W. and Y.W.) independently extracted the data from each eligible study. Any disagreements were resolved by discussion with a third review author (F.Q.). Data retrieved included characteristics of study, subjects and interventions, as well as outcome measures. Authors were contacted for additional or missing information as required.
Risk of bias
The risk of bias of the included studies was assessed independently by two authors (F.W. and Y.Z.) using the Cochrane Risk of Bias Tool 2.0 with respect to the following aspects: the randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported results. Any discrepancies were resolved among the authors to reach a consensus.
Statistical analysis
We extracted point estimates of relevant means and standard deviations from individual studies. This includes mean difference and its associated standard deviation (SD) between the comparison groups after the experiment. If the SD associated with the mean difference was not reported, then a 95% confidence interval (CI) was used for the computation of SD. Moreover, if the mean difference and associated SD between the comparison groups was not reported, we extracted the arm-specific mean and SD both before and after the treatment to calculate these quantities. The formula for computing the mean change and its associated SD for a specific arm referred to Dias et al. 25 . The mean of the comparison groups was assumed to follow a normal distribution and, therefore, the calculation of mean difference (and associated SD) was based on the subtraction of two independent normal distributions 26 . If the equal variance assumption is valid (i.e., the variances of the pairwise groups were comparable), the pooled SD was calculated as S pooled = √ We used standard meta-analyses with a random-effects model to examine any heterogeneity that may exist in each of the pairwise treatment comparisons (e.g. metformin versus placebo, orlistat versus metformin). The statistical heterogeneity was assessed with the 2 statistic and -value. In terms of inconsistency, heat plots were provided to visualise whether there was disagreement between direct and indirect comparisons 27, 28 .
Subgroup analysis was performed for studies that reported an outcome of interest (i.e., BMI, weight and waist circumference) with the same treatment duration (12 weeks or 24 weeks). A network meta-analysis was used for outcomes reported at 12 weeks (since more than two treatments were compared) whereas a standard meta-analysis was applied for outcomes reported at 24 weeks (only metformin and placebo were compared).
A funnel plot and a regression test that detected any asymmetry of the funnel plot were used to examine publication bias for standard meta-analysis. The -value associated with the Egger's test statistic was also reported.
Sensitivity analysis was conducted to explore the effect of the summary estimate by excluding studies that were considered to result in high heterogeneity (i.e., 2 > 50%) in the pairwise standard meta-analysis.
All the analyses were performed in R using the packages 'netmeta' (used for network meta-analysis) 29 and 'metafor' (used for standard meta-analysis) 30 .
Results

Search results
The search strategy yielded 4307 studies; however, 3848 studies were excluded because it was clear from the title or abstract that they did not fulfil the selection criteria.
After full-text review of 459 potential studies, we further excluded 15 duplicates, 318
studies not meeting the selection criteria and 100 studies due to lack of essential data (e.g., mean and SD of the change of BMI, body weight, waist circumference or WHR between before and after interventions cannot be retrieved or computed). A total number of 26 studies were included for the systemic review, among which three studies were excluded because different preparations of inositol were examined. This Participants aged 18 years to menopause were included in 24 studies, and two studies examined the effect of metformin on weight reduction in adolescent women 49, 50 . . Table 2 shows results from the risk of bias assessment.
Characteristics of included studies
Efficacy outcomes
The network of eligible comparison for efficacy is presented in Fig. 2 . Whilst metformin was directly compared with all the other treatments, the comparisons between the remaining four treatments (i.e., liraglutide alone, the combination of liraglutide and metformin, orlistat and placebo) were connected either directly or indirectly by at least one trial.
Our network meta-analysis included 23 RCTs with a total number of 941 participants.
Apart from four trials where a combination of liraglutide and metformin (60 women) was evaluated, the remaining trials offered a single drug as an intervention, including liraglutide (6 trials, of which 5 used a dose below the 3 mg licensed dose for obesity treatment, 118 women), metformin (19 trials, 338 women), orlistat (5 trials, 123 women) and placebo (14 trials, 302 women).
Compared with the placebo, all the interventions (liraglutide, metformin, orlistat, and liraglutide in combination with metformin) resulted in a significant reduction in BMI in women with PCOS and overweight/obesity (Fig. 3A) . The efficacy of all the treatments was compared pairwise (Table 3) . Using subgroup analysis, only orlistat significantly reduced BMI after 12 weeks of treatment ( Fig. 3B and Table 3 ). Similarly, there was no significant impact of metformin on BMI reduction after 24 weeks of treatment (Fig.   3C ). The funnel plot showed minor asymmetry (Fig. S1A) .
Compared with the placebo, all the interventions, liraglutide, metformin, orlistat and the combination of liraglutide and metformin, led to a significant decrease in weight (Fig.   4A ). The magnitude of weight reduction differed significantly among drugs (in descending order): liraglutide alone, orlistat and metformin alone (Table 4) . Liraglutide alone was more effective than liraglutide and metformin combined. This may reflect the higher liraglutide dose in studies of monotherapy than in those where it was used with metformin. At 12 weeks, only orlistat had a significant impact on BMI, whilst liraglutide alone and orlistat had a significant effect on weight ( Fig. 4B and Table 4 ).
The results from 24 weeks suggested that metformin was superior to the placebo (Fig.   4C ). Funnel plot analysis indicated no publication bias (Fig. S1B) .
The results for waist circumference ( Fig. 5 and Table 5 ) were mainly consistent with those for BMI and weight: liraglutide alone, liraglutide in combination with metformin and metformin alone led to a significant decrease in the waist circumference of women with PCOS and overweight/obesity (Fig. 5A ). Liraglutide alone was more effective than metformin ( Table 5 ). The reduction in waist circumference was not significant compared with the placebo for all treatments at 12 weeks ( Fig. 5B and Table 5 ). Waist circumference was significantly reduced after 24 weeks of metformin therapy (Fig. 5C ).
There was minor publication bias (Fig. S1C ).
Data for WHR were only available for metformin; metformin was not found to be superior to the placebo, based on results of all included studies (Fig. 6A ) or only 24-week studies (Fig. 6B) . Again, minor publication bias was present ( Fig. S1D and E) .
Pairwise meta-analysis showed significant heterogeneity ( 2 = 71%) for the direct comparison between metformin and the placebo (results for waist circumference based on all the included studies), but there was no heterogeneity ( 2 = 0) or moderate heterogeneity ( 2 < 25%) for all the remaining comparisons. No significant inconsistency was identified from our assessment based on the heat plots (Fig. S2 ).
Sensitivity analysis
One study 49 was excluded from the sensitivity analysis for waist circumference because it was the leading contributor to heterogeneity in the direct comparison between metformin and placebo. The results of the network meta-analysis after removing this study ( Fig. S3 and Table S1 ) were consistent with the previous results for waist circumference (Fig. 5A ).
Four trials 31, [48] [49] [50] were excluded in the sensitivity analysis for BMI, weight and waist circumference because the sample size was less than 10 per arm. The results of the network meta-analysis after removing these trials (Fig. S4A-C and Table S2A -C) were consistent with the previous results for BMI, weight and waist circumference (Fig. 3A, 4A and 5A).
Two studies 49, 50 were excluded from the sensitivity analysis for BMI and waist circumference because they included adolescents. However, none of these studies assessed weight loss. The results of the network meta-analysis after removing these studies ( Fig. S5A and B ; Table S3A and B) were consistent with the previous results for BMI and waist circumference ( Fig. 3A and 5A ).
Discussion
As far as we are aware, this is the first meta-analysis to compare the effects of the treatments currently used to induce weight loss in women with PCOS and overweight/obesity. The findings have important implications for clinical practice. We used network meta-analysis to simultaneously compare the efficacy of a range of interventions because a network allows for indirect comparisons of treatments which are not studied in a head-to-head fashion. For change in BMI and weight, all the drugs that qualified be evaluated in metaanalysis (liraglutide, metformin (alone and in combination) and orlistat) were superior to the placebo. There were, however, significant differences in the efficacy of these drugs; for weight loss, treatment with liraglutide was superior to all other treatments and orlistat was superior to metformin based on the data of all the included studies. .
With the exception of a few outcomes confined to orlistat and liraglutide, 12 weeks of treatment is ineffective, so treatment should be continued for at least 24 weeks and probably much longer as the available evidence suggests that lost weight is regained when treatment is stopped. However, orlistat is only licensed for three years use.
Liraglutide, a glucagon-like peptide-1 receptor agonist, was developed to treat type II diabetes 15 but weight loss has been well described as an additional benefit, which prompted the manufacturer to develop a higher dose formulation specifically for this indication 15 . Liraglutide is also used by some doctors to treat women who have obesity/overweight with PCOS. Orlistat, which has an established safety profile 64 , is a reversible inhibitor of gastric and pancreatic lipases. As it is generally well tolerated, orlistat is an option for treatment of patients affected by obesity with or without type II diabetes and also has a role in the management of patients with metabolic syndrome and obesity, associated comorbidities or concomitant disorders Although BMI is the most widely used measure of obesity, there is increasing evidence that waist circumference is more closely associated with insulin resistance (IR) 2, 68 .
Since waist circumference is positively correlated with the visceral adiposity index 69 and 98% of women with PCOS and metabolic syndrome have an abnormal waist circumference 70 , this measurement is particularly relevant to the present study. In support of this, waist circumference was found to be the simplest method of clinical screening for IR in women with hirsutism 68 . None of the drugs evaluated had a significant effect on waist circumference after 12 weeks. However, based on data of all the included studies, liraglutide and metformin (alone or in combination) were superior to the placebo. Data was not available for 24 weeks of therapy with the other treatments, but network analysis showed that liraglutide was superior to metformin after combining all the included studies.
The results of this analysis provide the first comparison of the drugs currently used to induce weight loss in women with PCOS and overweight/obesity. Effective therapy is urgently needed in view of the high prevalence of obesity in women with this syndrome, and its adverse effects on symptoms (including infertility) and increased risk of long term morbidity(e.g. diabetes and coronary heart disease) 2, 12 . Although all the drugs were superior to the placebo to induce weight loss, liraglutide was the most effective.
Liraglutide and metformin (alone or in combination) reduced waist circumference but, again, liraglutide was superior. Orlistat was superior to metformin in terms of weight loss but may be seen as inferior as it was not shown to reduce waist circumference.
Our results also suggest that 12 weeks of treatment was not effective. Finally, the relative efficacy of the three drugs must be judged against their cost, with liraglutide being 100-fold and orlistat 10-fold more expensive than metformin. As metformin, liraglutide and orlistat were being assessed for their effects on obesity, rather than overweight or symptoms of PCOS, lifestyle modification is an essential adjunct to pharmacologic therapy in this situation.
The present study has some limitations. Firstly, publication bias may exist given that studies with significant results are more likely to be published, although we have attempted to address this issue by retrieving all the available studies and a funnel plot was used to assess any bias that may have arisen from this source. Secondly, we
could not perform an analysis for the different inositol isomers. Data for the effects of 24 weeks of treatment were only available for metformin. Two studies 49, 50 were confined to treating adolescent patients with PCOS. Finally, there was high heterogeneity for the comparison between metformin and placebo with respect to waist circumference, which was considered to be caused by one study 49 where an increase This study focused on the effects of the currently available drugs that are most commonly used to treat women with PCOS and obesity. However, new and possibly more effective anti-obesity drugs such as semaglutide (a once weekly GLP-1 agonist which induces weight loss of around 13.8%) 71 , bupropion/naltrexone and lorcaserin are now available, and these may have an important role in treating women with PCOS.
Conclusion
The results of this study provide evidence that the three treatments with data suitable for analysis (liraglutide, metformin and orlistat) reduce BMI and weight in women with PCOS and overweight/obesity. Although effective, they are adjunct to, not a replacement for, a low energy diet and increased physical activity. Using network analysis, we found that liraglutide was the most effective and metformin the least effective intervention to lower BMI and weight. In view of the fact that the obesity that affects women with PCOS is predominantly central and this visceral fat is associated with anovulation, diabetes and cardiovascular morbidity, we also assessed the effects of these drugs on waist circumference. For this endpoint, liraglutide was again more effective than metformin, but we did not find a statistically significant effect for orlistat.
In clinical practice, effectiveness has to be weighed against cost. We have not performed an economic evaluation, but on the basis that the cost of liraglutide is approximately 100-fold more expensive than metformin and 10-fold more expensive than orlistat, it seems unrealistic to suggest widespread use of this drug for this indication. The relative cost effectiveness of orlistat and metformin is less obvious, with orlistat having the benefit of greater weight loss but the possible disadvantage of a lesser effect on visceral fat. In the absence of a healthy economic evaluation, the results of our analysis support the use of either metformin or orlistat to induce weight loss in women with PCOS and overweight/obesity. However, the conclusion may seem limited due to the insufficient evidences to date to guide policy recommendations.
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